Test To Distinguish Between
Bipolar Disorder and Depression
(February 9, 2007) --
Type II bipolar disorder is an underdiagnosed
disease which can be easily confused with
depression. Contrarily to what
happens in type I bipolar disorder,
depressive symptoms and, above all,
manic symptoms alternated in this form of the disease are not evident and
difficult to identify.
In fact, patients suffering from it usually go to the doctor because they
are depressed, without thinking that they have also had slight manic
episodes (euphoria and other cognition disorders). Right now, the medical
profession lacks tools
to successfully identify this pathology, which, on average, can take 8-10 years to be
correctly diagnosed. Furthermore,
antidepressant treatment can be
counterproductive in patients with type II bipolar disorder.
Dr. Eduard Vieta, of the group Biological Basis of the Psychic Disorder and Nuclear
Psychiatry of the Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS),
has coordinated a study in order to validate the Spanish version of the test
Hypomania symptom check list (HCL-32), which is being developed in
collaboration with other professionals internationally.
The last issue of the Journal of Affective Disorders published results
confirming the usefulness of this simple questionnaire, consisting of 32 questions, to
distinguish major depression from bipolar disorder. In 2005, researchers
from IDIBAPS collaborated in the international design of this test (J Affect
Disord, 2005; 88(2):217-33). The main difference between HCL-32 and the test
used until today -the Mood disorder questionnaire (MDQ)- is the open
character of the questions, facilitating the patient’s sincerity. In these
questions lay essential information to assess retrospectively the
energy/activity levels of patients and problems of disinhibition,
self-control and attention they have suffered in the past.
This new study
compares the sensitivity of both questionnaires, and concludes that the
HCL-32 is more precise than the MDQ in the identification of type II bipolar
disorder patients. This work has been supported by GlaxoSmithKline (GSK) and
had the participation of PSYNCRO, a neuropsychological research enterprise,
located in the Parc Científic de Barcelona (PCB), which has worked in
collaboration with the Department of Psychology of the Universitat de Girona.
A total of
237 people from 15 different psychiatric departments (see annex list),
filled out the HCL-32. Except those belonging to the control group (60), the
rest were correctly diagnosed, stable and receiving a correct treatment for
their pathology, which could be type I (62) and type II (56) bipolar
disorder, or major depression (58). This test was able to identify more than
80% of patients with bipolar disorder. Although it could not distinguish
between types I and II, this decision is relatively easy to take from the
clinical data of the patient. For the first time, a tool to identify bipolar
disorder is available for patients going to the medical centre claiming
depression. Although it is necessary to go on with studies in patients of
wider populations, the HCL-32 test can provide very useful information to
psychiatrists and even to primary-care physicians.-IDIBAPS - Institut
d'Investigacions Biomèdiques August Pi i Sunyer
Source: harminka
Last updated: 2/07
Related Information:
back to
top ~ bipolar news index ~
send page to a
friend |